G. Bruixola

588 total citations
22 papers, 370 citations indexed

About

G. Bruixola is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, G. Bruixola has authored 22 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in G. Bruixola's work include Head and Neck Cancer Studies (5 papers), Cancer Genomics and Diagnostics (5 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). G. Bruixola is often cited by papers focused on Head and Neck Cancer Studies (5 papers), Cancer Genomics and Diagnostics (5 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). G. Bruixola collaborates with scholars based in Spain, United States and Japan. G. Bruixola's co-authors include Andrés Cervantes, S. Zúñiga, Marisol Huerta, Carolina Martínez‐Ciarpaglini, Desamparados Roda, Francisco Gimeno-Valiente, D Moro, Susana Roselló, Tania Fleitas and Alejandro Espí and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

G. Bruixola

16 papers receiving 367 citations

Peers

Countries citing papers authored by G. Bruixola

Since Specialization

Citations

This map shows the geographic impact of G. Bruixola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Bruixola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Bruixola more than expected).

Fields of papers citing papers by G. Bruixola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Bruixola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Bruixola. The network helps show where G. Bruixola may publish in the future.

Co-authorship network of co-authors of G. Bruixola

This figure shows the co-authorship network connecting the top 25 collaborators of G. Bruixola. A scholar is included among the top collaborators of G. Bruixola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Bruixola. G. Bruixola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer 2025 ·ESMO Open ·G. Bruixola, (unknown), Francisco Gimeno-Valiente, Juan Antonio Carbonell‐Asins, (unknown), (unknown), (unknown), (unknown), (unknown), Clara Alfaro‐Cervelló, (unknown), (unknown), (unknown), (unknown), (unknown), N. Tarazona	0
2	Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations 2025 ·ESMO Open ·(unknown), Juan Antonio Carbonell‐Asins, (unknown), (unknown), (unknown), Carolina Martínez‐Ciarpaglini, José González, Paloma Martín-Martorell, (unknown), (unknown), (unknown), (unknown), G. Bruixola, Amelia Insa, Juan Miguel Cejalvo, Tania Fleitas, N. Tarazona, (unknown), Desamparados Roda, Valentina Gambardella	0
3	871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study 2024 ·Annals of Oncology ·Lara Iglesias Docampo, (unknown), (unknown), Ana Maseda, Pedro Pérez Segura, Ana Medina, Beatriz Cirauqui, (unknown), Javier Martínez‐Trufero, (unknown), (unknown), (unknown), (unknown), (unknown), E. del Barco, G. Bruixola, M.J. Flor, (unknown), (unknown), (unknown)	0
4	CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer 2024 ·European Radiology ·G. Bruixola, (unknown), Ana Jiménez-Pastor, (unknown), (unknown), (unknown), Clara Alfaro‐Cervelló, (unknown), (unknown), (unknown), (unknown), (unknown), Ángel Alberich‐Bayarri, Andrés Cervantes, Noelia Tarazona	4
5	First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Alan L. Ho, (unknown), (unknown), Amy K. Sauer, (unknown), (unknown), (unknown), (unknown), Maura L. Gillison, John A. Charlson, (unknown), Jon Zugazagoitia, Emiliano Calvo, (unknown), G. Bruixola, Víctor Moreno, David S. Hong, (unknown), David H. Aggen	2
6	Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study 2024 ·Clinical & Translational Oncology ·Paloma Navarro, Carmen Beato, Juan Francisco Rodríguez-Moreno, Sergio Ruiz‐Llorente, Xabier Mielgo-Rubio, Estela Pineda, M Navarro, G. Bruixola, (unknown), A. Viúdez, José Luís Fuster, (unknown), (unknown), Carmen Balañá, Carlos Mendez‐Dorantes, (unknown), Sonia Del Barco Berrón, (unknown), Alberto Carmona‐Bayonas, Jesús García-Donás	0
7	Development of CT-based radiomic model to predict 5-year progression-free survival (PFS) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with definitive chemoradiation. 2023 ·Journal of Clinical Oncology ·G. Bruixola, (unknown), (unknown), (unknown), Ana Jiménez-Pastor, (unknown), (unknown), (unknown), (unknown), (unknown), Clara Alfaro‐Cervelló, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Noelia Tarazona, Ángel Alberich‐Bayarri, Andrés Cervantes	0
8	Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review 2021 ·Annals of Translational Medicine ·Yan Li, Tomoki Nakamura, Andrea Casadei‐Gardini, G. Bruixola, Yuan‐Lan Huang, (unknown)	37
9	Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges 2021 ·Cancer Treatment Reviews ·G. Bruixola, (unknown), Ana Jiménez-Pastor, (unknown), (unknown), (unknown), Maider Ibarrola‐Villava, Ángel Alberich‐Bayarri, Andrés Cervantes	34
10	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer 2019 ·Annals of Oncology ·N. Tarazona, Francisco Gimeno-Valiente, Valentina Gambardella, S. Zúñiga, Pilar Rentero-Garrido, Marisol Huerta, Susana Roselló, Carolina Martínez‐Ciarpaglini, Juan Antonio Carbonell‐Asins, (unknown), (unknown), G. Bruixola, Tania Fleitas, (unknown), (unknown), D Moro, Josefa Castillo, Alejandro Espí, Desamparados Roda, Andrés Cervantes	190
11	Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer 2018 ·ESMO Open ·G. Bruixola, Javier Caballero‐Villarraso, Federica Papaccio, Angelica Petrillo, (unknown), Miguel Civera, (unknown), (unknown), (unknown), (unknown), Miguel Ángel Aguirre, Andrés Cervantes	50
12	Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience 2018 ·Annals of Oncology ·G. Bruixola, (unknown), (unknown), (unknown), (unknown), (unknown), Sebastián Ochenduszko, A. Iranzo, Javier Lavernia, (unknown), Miguel Pastor Borgoñón	1
13	Controversies in the multimodality management of locally advanced rectal cancer 2017 ·Medical Oncology ·Robert Díaz Beveridge, Dilara Akhoundova, G. Bruixola, Jorge Aparicio	13
14	An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib 2017 ·Clinical & Translational Oncology ·Robert Díaz Beveridge, G. Bruixola, David Lorente, Javier Caballero‐Villarraso, (unknown), Ángel Segura, Dilara Akhoundova, (unknown), Jorge Aparicio	14
15	Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma 2015 ·Journal of Pediatric Hematology/Oncology ·Robert Díaz Beveridge, David Lorente, Bárbara Torres, Adela Cañete, (unknown), G. Bruixola, Pablo Berlanga, (unknown), Joaquín Montalar, Amparo Verdeguer, Jorge Aparicio	6
16	Transarterial chemoembolization with doxorubicin-loaded drug-eluting beads (DEBDOX) in the treatment of breast cancer liver metastases: A pilot study 2015 ·Annals of Oncology ·G. Bruixola, (unknown), (unknown), (unknown), Laura Palomar, (unknown), (unknown), Ana Santaballa	1
17	Adjuvant Chemoradiation in Gastric Cancer: Long-term Outcomes and Prognostic Factors from a Single Institution 2015 ·Tumori Journal ·G. Bruixola, Ángel Segura, Robert Díaz Beveridge, Javier Caballero‐Villarraso, (unknown), Laura Palomar, (unknown), (unknown), (unknown), Jorge Aparicio	2
18	Feasibility and Safety of a Modified Outpatient Regimen With Intravenous/Intraperitoneal Chemotherapy for Optimally Debulked Stage III Ovarian Cancer 2014 ·International Journal of Gynecological Cancer ·G. Bruixola, Santiago Domingo, Roberto Díaz, Javier Caballero‐Villarraso, Laura Palomar, (unknown), Ana Santaballa	3
19	Pleuropulmonary angiosarcoma involving the liver, the jejunum and the spine, developed from chronic tuberculosis pyothorax: Multidisciplinary approach and review of literature 2014 ·Lung Cancer ·G. Bruixola, Robert Díaz Beveridge, (unknown), Javier Caballero‐Villarraso, Miguel Salavert, (unknown), Jorge Aparicio	2
20	Heart Failure as First Sign of Development of Cardiac Metastases in a Patient with Diagnosis of Papillary Thyroid Carcinoma on Treatment with Tyrosine-Kinase Inhibitors: Differential Diagnoses and Clinical Management 2014 ·Case Reports in Oncology ·G. Bruixola, Ángel Segura, Javier Caballero‐Villarraso, Ana Andrés, (unknown), (unknown), Robert Díaz Beveridge	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact